Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Joao Diogo Da Rocha Fernandes"'
Publikováno v:
Advances in Therapy
Introduction The aim of this study was to evaluate the glycemic control and safety of insulin degludec/insulin aspart (IDegAsp) co-formulation in Japanese patients with type 2 diabetes (T2D) in a real-world clinical setting, including elderly patient
Autor:
Jens Gundgaard, Ann Charlotte Mårdby, Barnaby Hunt, Åsa Ericsson, Johan Jendle, Joao Diogo Da Rocha Fernandes, Bertil Ekman, Samuel J. P. Malkin, Maria Thunander, Stefan Sjöberg
Publikováno v:
Journal of Medical Economics. 23:1311-1320
Background and Aims: The ReFLeCT study demonstrated that switching to insulin degludec from other basal insulins was associated with reductions in glycated hemoglobin and hypoglycemic events in type 1 (T1D) and type 2 diabetes (T2D), and reductions i
Autor:
Mervete Miftaraj, Joao Diogo Da Rocha Fernandes, Ann-Marie Svensson, Björn Eliasson, Mattis F. Ranthe, Ann-Charlotte Mårdby, Jan Ekelund
Publikováno v:
Diabetes Therapy
Aims To explore persistence with insulin degludec/liraglutide (IDegLira) treatment, clinical characteristics and concomitant medications in a large population of patients in clinical practice. Methods This was an observational study in patients with
Autor:
Alina Bogdanov, Leonard E. Egede, Joao Diogo Da Rocha Fernandes, Lauren Fischer, Lee Kallenbach
Publikováno v:
Diabetes Therapy
Introduction IDegLira is a fixed-ratio combination of insulin degludec and liraglutide indicated for the treatment of type 2 diabetes (T2D). We report the first real-world study describing change in glycated hemoglobin (HbA1c) among US patients who i
Autor:
William H. Polonsky, Marc Evans, Joao Diogo Da Rocha Fernandes, Susanne Engberg, Mads Faurby, Pollyanna Hudson
Publikováno v:
Diabetes, obesitymetabolism. 24(3)
We designed a systematic literature review to identify available evidence on adherence to and persistence with antidiabetic medication in people with type 2 diabetes (T2D). Electronic screening and congress searches identified real-world non-interven
Publikováno v:
Diabetes. 70
Introduction: Reducing dosing frequency may reduce treatment burden and improve adherence and persistence. We assessed persistence and adherence in patients with T2D initiating once-weekly (OW) or once-daily (OD) injectable glucagon-like peptide-1 re
Autor:
Jan Ekelund, Björn Eliasson, Ann-Marie Svensson, Joao Diogo Da Rocha Fernandes, Mervete Miftaraj, Ann-Charlotte Mårdby
Publikováno v:
Diabetes. 68
This retrospective study examines outcomes associated with use of IDegLira - a fixed-ratio insulin degludec/liraglutide combination - in a large real-world cohort of patients with type 2 diabetes in Sweden. Data were obtained from the Swedish Nationa
Autor:
Michelle Mocarski, Michael Radin, Alina Bogdanov, Joseph Vasey, Joao Diogo Da Rocha Fernandes, Jessica Ken, Leonard E. Egede, Lee Kallenbach
Publikováno v:
Diabetes. 67
Background: IDegLira, a fixed-ratio combination of a basal insulin (BI), insulin degludec, and liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1), was approved by the FDA in Q4 2016 for the treatment of type 2 diabetes Mellitus (T2DM). T
Autor:
Sarah Eggert, Esther Zimmermann, Adam Lenart, Joao Diogo Da Rocha Fernandes, Mattis F. Ranthe
Publikováno v:
Diabetes. 67
Machine learning allows extensive analysis of big complex data. This study had two aims: 1) characterize patients on BI who add a GLP-1RA and 2) identify predictors of ≥1% decline in A1C. Patients with T2D who were prescribed BI for ≥90 days but
Autor:
Jina Hahn, Alina Bogdanov, Leonard E. Egede, Joao Diogo Da Rocha Fernandes, Lauren Fischer, Lee Kallenbach
Publikováno v:
Canadian Journal of Diabetes. 43:S36